Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phentermine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.91 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.91 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phentermine SCHEMBL10392295 | 0.95 | SLC6A2 (1.00) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL26615 | 0.95 | SLC6A2 (1.00) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL41585 | 0.93 | SLC6A2 (0.95) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL28695767 | 0.93 | SLC6A2 (0.95) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL3676484 | 0.93 | SLC6A2 (0.95) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL28729624 | 0.93 | SLC6A2 (0.95) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL25214698 | 0.91 | SLC6A2 (0.91) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL29261099 | 0.91 | SLC6A2 (0.91) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| Phentermine SCHEMBL8825530 | 0.87 | SLC6A2 (0.76) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| SCHEMBL11709671 | 0.86 | SLC6A2 (0.83) | SLC6A2TAAR1HTR2ASLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205222-A1 | ANTIOBESITY COMPOSITIONS | JACKSON MILTON S (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250195455-A1 | COMBINATION NASAL AND ORAL THERAPY FOR WEIGHT LOSS | JACKSON MILTON S (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4493172-A1 | ANTIOBESITY COMPOSITIONS | Jackson, Milton S. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-118922180-A | Anti-obesity composition | 米尔顿·S·杰克逊 | 2024-11-08 | — | — | CN | disclosed |
| CN-118871099-A | Combined nasal and oral therapy for weight loss | 米尔顿·S·杰克逊 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023183153-A1 | COMBINATION NASAL AND ORAL THERAPY FOR WEIGHT LOSS | JACKSON MILTON S (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023177561-A1 | ANTIOBESITY COMPOSITIONS | JACKSON MILTON S (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230265043-A1 | CRYSTALLINE FORM OF PHENTERMINE HYDROCHLORIDE AND PROCESS FOR OBTAINING SAME | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-08-24 | — | — | US | disclosed |
| EP-4190320-A1 | CRYSTALLINE FORM OF PHENTERMINE HYDROCHLORIDE AND PROCESS FOR OBTAINING SAME | Eurofarma Laboratórios S.A. (BR) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022020910-A1 | CRYSTALLINE FORM OF PHENTERMINE HYDROCHLORIDE AND PROCESS FOR OBTAINING SAME | EUROFARMA LABORATÓRIOS S.A. (BR) | 2022-02-03 | — | — | WO | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | SLC6A2 330/4885TAAR1 282/4885HTR2A 524/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | SLC6A2 2832/4885TAAR1 2834/4885HTR2A 3184/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | SLC6A2 1018/4885TAAR1 944/4885HTR2A 1221/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | SLC6A2 295/4885TAAR1 326/4885HTR2A 273/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A2 1348/4885TAAR1 207/4885HTR2A 406/4885 |
| US-20230265043-A1 | CRYSTALLINE FORM OF PHENTERMINE HYDROCHLORIDE AND PROCESS FOR OBTAINING SAME | PNMT, HTR5A, TAAR5 | SLC6A2 6/4885TAAR1 14/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.